JP2022513068A5 - - Google Patents

Info

Publication number
JP2022513068A5
JP2022513068A5 JP2021526801A JP2021526801A JP2022513068A5 JP 2022513068 A5 JP2022513068 A5 JP 2022513068A5 JP 2021526801 A JP2021526801 A JP 2021526801A JP 2021526801 A JP2021526801 A JP 2021526801A JP 2022513068 A5 JP2022513068 A5 JP 2022513068A5
Authority
JP
Japan
Prior art keywords
cancer
loh
sample
tmb
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513068A (ja
JP7623281B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061710 external-priority patent/WO2020102674A1/en
Publication of JP2022513068A publication Critical patent/JP2022513068A/ja
Publication of JP2022513068A5 publication Critical patent/JP2022513068A5/ja
Priority to JP2024168315A priority Critical patent/JP2025000809A/ja
Application granted granted Critical
Publication of JP7623281B2 publication Critical patent/JP7623281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526801A 2018-11-15 2019-11-15 免疫療法で治療されたがん患者の応答の予測を改善する方法 Active JP7623281B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024168315A JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767979P 2018-11-15 2018-11-15
US62/767,979 2018-11-15
PCT/US2019/061710 WO2020102674A1 (en) 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024168315A Division JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Publications (3)

Publication Number Publication Date
JP2022513068A JP2022513068A (ja) 2022-02-07
JP2022513068A5 true JP2022513068A5 (https=) 2024-03-11
JP7623281B2 JP7623281B2 (ja) 2025-01-28

Family

ID=70727341

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526801A Active JP7623281B2 (ja) 2018-11-15 2019-11-15 免疫療法で治療されたがん患者の応答の予測を改善する方法
JP2024168315A Pending JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024168315A Pending JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Country Status (6)

Country Link
US (2) US12497661B2 (https=)
EP (1) EP3880246A4 (https=)
JP (2) JP7623281B2 (https=)
AU (1) AU2019379167A1 (https=)
CA (1) CA3120200A1 (https=)
WO (1) WO2020102674A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230056761A (ko) * 2020-08-26 2023-04-27 리제너론 파마슈티칼스 인코포레이티드 Pd-1 저해제의 투여에 의한 암 치료 방법
CN111979323A (zh) * 2020-08-28 2020-11-24 深圳裕策生物科技有限公司 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统
CN112029861B (zh) * 2020-09-07 2021-09-21 臻悦生物科技江苏有限公司 基于捕获测序技术的肿瘤突变负荷检测装置及方法
WO2022232503A1 (en) * 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2023196390A1 (en) * 2022-04-06 2023-10-12 Foundation Medicine, Inc. Aneuploidy biomarkers associated with response to anti-cancer therapies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531279B1 (en) * 1998-04-15 2003-03-11 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
EP3012329B1 (en) * 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
KR20230030022A (ko) * 2014-11-13 2023-03-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
CN117467603A (zh) 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CA3015913A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
CN114959918A (zh) * 2016-02-29 2022-08-30 基础医疗股份有限公司 用于评估肿瘤突变负荷的方法和系统
JP6821693B2 (ja) * 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
US20190247435A1 (en) 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
EP3516081A4 (en) 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
WO2018071796A2 (en) 2016-10-13 2018-04-19 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
US11634777B2 (en) * 2017-01-13 2023-04-25 The General Hospital Corporation Resistance to checkpoint blockade therapy
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
CN117987553A (zh) * 2017-09-25 2024-05-07 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法

Similar Documents

Publication Publication Date Title
JP2022513068A5 (https=)
JP7851982B2 (ja) 癌のための個別化ワクチン
US20250313825A1 (en) Methods of capturing cell-free methylated dna and uses of same
Iacono et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study
Chang et al. Clinical application of amplicon-based next-generation sequencing in cancer
Reon et al. Expression of lncRNAs in low-grade gliomas and glioblastoma multiforme: an in silico analysis
Oyama et al. Isolation of a novel gene on 8p21. 3–22 whose expression is reduced significantly in human colorectal cancers with liver metastasis
US20160095920A1 (en) Kras mutations and resistance to anti-egfr treatment
Nome et al. Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing
Rechsteiner et al. KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics
Nome et al. High frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel fusion partner and splice variants
Noh et al. Targeted liquid biopsy using irradiation to facilitate the release of cell-free DNA from a spatially aimed tumor tissue
KR101838394B1 (ko) 뇌실하 영역의 돌연변이 유전자를 이용한 교모세포종 조직 기원의 예측 방법 및 동물 모델
Romero et al. Polymorphisms in TWIST1 and ZEB1 are associated with prognosis of gastric cancer patients
JP2024529192A (ja) 組織損傷を検出するための循環無細胞メチル化ｄｎａの使用
Koh et al. Detection of a distinctive genomic signature in rhabdoid glioblastoma, a rare disease entity identified by whole exome sequencing and whole transcriptome sequencing
KR20150132206A (ko) 예측성 바이오마커에 대한 검정법
CN105506155A (zh) 检测长链非编码rna loc284454表达量的试剂的应用
Xu et al. A pan-cancer analysis of cystatin E/M reveals its dual functional effects and positive regulation of epithelial cell in human tumors
Wang et al. Oncogenes expand during evolution to withstand somatic amplification
KR102083956B1 (ko) 다발성 골수종 환자에서 레날리도마이드 및 덱사메타손의 치료에 대한 예후 예측용 바이오 마커
Zhou et al. Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers
Parsafar et al. Polymorphic GT dinucleotide repeat in the PIK3CA gene and risk of colorectal cancer
CN104928377A (zh) 一种CYP2C19*3基因多态性SNaPshot检测方法与应用
Ninomiya et al. Application of deep sequence technology in hepatology